bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting Read more about bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting
bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy Read more about bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy
bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition Read more about bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition
bluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress Read more about bluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress
bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh Read more about bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh
European Medicines Agency Approves Refined Commercial Manufacturing Specifications for ZYNTEGLO™ Read more about European Medicines Agency Approves Refined Commercial Manufacturing Specifications for ZYNTEGLO™
bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases Read more about bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases
bluebird bio Appoints William R. Sellers, M.D. to Board of Directors Read more about bluebird bio Appoints William R. Sellers, M.D. to Board of Directors
bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress Read more about bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress